» Articles » PMID: 32140359

Use of Valbenazine in a 54-Year-Old Female with Severe Tardive Dyskinesia

Overview
Journal Cureus
Date 2020 Mar 7
PMID 32140359
Authors
Affiliations
Soon will be listed here.
Abstract

Tardive dyskinesia (TD) is a serious and often irreversible involuntary muscle movement that involves the face, lips, tongue, trunk, and extremities. TD is a risk in the use of antipsychotic medications, whether it is typical or first generation or atypical or second-generation antipsychotic. The risk is highest in patients receiving long-term antipsychotic treatment. Before the availability of valbenazine, clozapine was used to reverse or at least ameliorate TD. We report a case of a patient on long-term antipsychotic treatment whose TD was initially reversed by clozapine but was completely reversed by valbenazine.

References
1.
Kumet R, Freeman M . Clozapine and tardive dyskinesia. J Clin Psychiatry. 2002; 63(2):167-8. DOI: 10.4088/jcp.v63n0213d. View

2.
Dalack G, Becks L, Meador-Woodruff J . Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22(4):567-73. DOI: 10.1016/s0278-5846(98)00026-8. View

3.
Correll C, Kane J, Citrome L . Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017; 78(8):1136-1147. DOI: 10.4088/JCP.tv17016ah4c. View

4.
Cornett E, Novitch M, Kaye A, Kata V, Kaye A . Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J. 2017; 17(2):162-174. PMC: 5472076. View

5.
OBrien C, Jimenez R, Hauser R, Factor S, Burke J, Mandri D . NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015; 30(12):1681-7. PMC: 5049616. DOI: 10.1002/mds.26330. View